These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38594880)

  • 21. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
    Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
    J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin
    Reinmuth N; Bryl M; Bondarenko I; Syrigos K; Vladimirov V; Zereu M; Bair AH; Hilton F; Liau K; Kasahara K
    BioDrugs; 2019 Oct; 33(5):555-570. PubMed ID: 31338773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
    Tanaka H; Hasegawa Y; Makiguchi T; Okumura F; Tabe C; Shiratori T; Ishioka Y; Itoga M; Taima K; Yokouchi J; Hatayama Y; Aoki M; Tasaka S
    Clin Lung Cancer; 2021 Jan; 22(1):42-48. PubMed ID: 33158764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
    Morgensztern D; Cobo M; Ponce Aix S; Postmus PE; Lewanski CR; Bennouna J; Fischer JR; Juan-Vidal O; Stewart DJ; Fasola G; Ardizzoni A; Bhore R; Wolfsteiner M; Talbot DC; Jin Ong T; Govindan R; On Behalf Of The Abound L Investigators
    Cancer; 2018 Dec; 124(24):4667-4675. PubMed ID: 30383906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.
    Twelves C; Chmielowska E; Havel L; Popat S; Swieboda-Sadlej A; Sawrycki P; Bycott P; Ingrosso A; Kim S; Williams JA; Chen C; Olszanski AJ; de Besi P; Schiller JH
    Ann Oncol; 2014 Jan; 25(1):132-8. PubMed ID: 24356624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
    Eberhardt WE; Mitchell P; Schiller JH; Brown MP; Thomas M; Mills G; Jehl V; Urva SR; De Leo JJ; Gogov S; Papadimitrakopoulou V
    Invest New Drugs; 2014 Feb; 32(1):123-34. PubMed ID: 23579358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.
    Gridelli C; Chen T; Ko A; O'Brien ME; Ong TJ; Socinski MA; Postmus PE
    Drug Des Devel Ther; 2018; 12():1445-1451. PubMed ID: 29872267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.
    Kim ES; Moon J; Herbst RS; Redman MW; Dakhil SR; Velasco MR; Hirsch FR; Mack PC; Kelly K; Heymach JV; Gandara DR
    J Thorac Oncol; 2013 Dec; 8(12):1519-28. PubMed ID: 24189513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
    Kenmotsu H; Yoh K; Mori K; Ono A; Baba T; Fujiwara Y; Yamaguchi O; Ko R; Okamoto H; Yamamoto N; Ninomiya T; Ogura T; Kato T
    Cancer Sci; 2019 Dec; 110(12):3738-3745. PubMed ID: 31608537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
    Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
    Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    Marrone KA; Zhou X; Forde PM; Purtell M; Brahmer JR; Hann CL; Kelly RJ; Coleman B; Gabrielson E; Rosner GL; Ettinger DS
    Oncologist; 2018 Jul; 23(7):859-865. PubMed ID: 29487223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
    Okamoto I; Yamamoto N; Kubota K; Ohe Y; Nogami N; Murakami H; Yamaya H; Ono K; Nakagawa K
    Invest New Drugs; 2012 Jun; 30(3):1132-7. PubMed ID: 21537886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.
    Niho S; Kunitoh H; Nokihara H; Horai T; Ichinose Y; Hida T; Yamamoto N; Kawahara M; Shinkai T; Nakagawa K; Matsui K; Negoro S; Yokoyama A; Kudoh S; Kiura K; Mori K; Okamoto H; Sakai H; Takeda K; Yokota S; Saijo N; Fukuoka M;
    Lung Cancer; 2012 Jun; 76(3):362-7. PubMed ID: 22244743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
    Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Nov; 125():136-141. PubMed ID: 30429011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
    Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
    J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
    Kogure Y; Iwasawa S; Saka H; Hamamoto Y; Kada A; Hashimoto H; Atagi S; Takiguchi Y; Ebi N; Inoue A; Kurata T; Okamoto I; Yamaguchi M; Harada T; Seike M; Ando M; Saito AM; Kubota K; Takenoyama M; Seto T; Yamamoto N; Gemma A
    Lancet Healthy Longev; 2021 Dec; 2(12):e791-e800. PubMed ID: 36098037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).
    Argiris A; Lee JW; Stevenson J; Sulecki MG; Hugec V; Choong NW; Saltzman JN; Song W; Hansen RM; Evans TL; Ramalingam SS; Schiller JH
    Ann Oncol; 2017 Dec; 28(12):3037-3043. PubMed ID: 28950351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.